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Our improved understanding behind the molecular mechanisms 
of tumorigenesis has facilitated the development of novel treat-
ments for cancer. These are often small molecule natural prod-
ucts which have potent cytotoxic activity that inhibit the growth 
of cancerous cells. However, these chemotherapeutic drugs of-
ten have multiple biochemical targets that make it difficult to se-
lectively target cancer cells. Antibody-Drug Conjugates (ADC) 
are cytotoxic agents that are chemically attached to monoclonal 
antibodies that target cancer-specific antigens. ADCs using the 
humanized antibody trastuzumab can facilitate the internaliza-
tion of the drug by first binding to the human epidermal growth 
factor receptor 2 (HER2) which are over expressed on the sur-
face of breast cancer cells in aggressive tumour types. With 
a lower risk of off-target side-effects, we present the use of a 
more potent cytotoxic agent with dual anticancer modes of ac-
tion known as the illudin--a novel sesquiterpene that is derived 
from Omphalotus mushrooms with high therapeutic value. We 
first propose chemical modifications of illudin analogues to max-
imize both affinity to glutathione reductase and DNA damaging 
ability. By analyzing the chemical mechanisms of cytotoxicity 
and carrying out protein-docking simulations, an optimized illu-
din analogue can be generated. We then propose the construc-
tion of SLAK-1, an ADC that consists of a HER2 targeting anti-
body (Trastuzumab) and an illudin analogue that are attached 
to each other via a non-reducible thioether linker (SMCC).
L’amélioration de notre compréhension vis-à-vis les mé-
canismes moléculaires tumorigenèse à faciliter le développe-
ment de nouveaux traitements pour le cancer. Ce sont habitu-
ellement de petits produits naturels qui détiennent une activité 
cytotoxique puissante inhibant la croissance de cellules can-
céreuses. Toutefois, ces médicaments chimiothérapeutiques 
ont souvent de multiples cibles biochimiques ce qui rend diffi-
cile de cibler sélectivement les cellules cancéreuses. Les con-
jugués anticorps-médicament (ADC = antibody-drug conju-
gate) sont des agents cytotoxiques qui sont liés chimiquement
In 1908, Paul Ehrlich promoted a 
concept termed the “magic bullet”: 
if a compound could be made se-
lective for a pathogen, then a toxin 
against the pathogen can be com-
bined with this compound to selec-
tively deliver it to its target. Speci-
ficity is a crucial consideration in 
drug design, as adverse side ef-
fects are caused by promiscuous 
off-target interactions. Anticancer 
drugs are particularly notorious 
for side effects since they are typi-
cally extremely cytotoxic and have 
poor inherent specificity. Here, 
the authors describe a strategy to 
specifically target breast cancer 
cells by using a Her-2 antibody to 
deliver a potent cytotoxic illudin 
analogue optimized via compu-
tational modeling. The antibody’s 
specificity to breast cancer cells 
arises from the differential expres-
sion of a membrane receptor, Her-
2, which is overexpressed in can-
cer cells. When the antibody binds 
to Her-2, a chemically conjugated 
illudin analogue can be internal-
ized within the cell. This proposal 
is very current within the field of 
cancer immunotherapy; cytotox-
ins conjugated to antibodies, or 
“magic bullets”, are just coming to 
market in the last few years.
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à des anticorps monoclonaux qui ciblent à leur tour des antigènes spécifiques au cancer. L’ADC utilisant 
l’anticorps humain Trastuzumab peut faciliter l’internalisation du médicament en se liant tout d’abord au 
récepteur du facteur de croissance épidermique humain 2 (HER2) qui sont surexprimés à la surface des 
cellules du cancer du sein dans des tumeurs de types agressifs. Avec un risque plus faible d’effets sec-
ondaires hors cible, on présente l’utilisation d’un agent cytotoxique plus puissant avec une double action 
anticancéreuse connu sous le nom d’illudine – un nouveau sesquiterpène dérivé du champignon Ompha-
lotus qui détient une haute valeur thérapeutique. Nous proposons d'abord des modifications chimiques 
à aux analogues d’illudine afin de maximiser à la fois affinité à la réductase glutathion et à sa capacité à 
endommager l'ADN. En analysant les mécanismes chimiques de la cytotoxicité et en menant des simu-
lations d’amarrage de protéines (« docking »), un analogue d’illudine optimisé peut être généré. Nous 
proposons ensuite la construction de SLAK-1, un ADC qui consiste d'un anticorps ciblant HER2 (Trastu-
zumab) et un analogue d’illudine qui sont liés entre-elles par un lien thioéther non réductible (SMCC). 
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Introduction
Breast cancer is the most prominent form of can-
cer in women worldwide and contributes to approxi-
mately 16% of cancer affecting females. An increase 
in the prevalence of the disease is evident in devel-
oping countries due to an increase in urbanization, 
life expectancy, and Western lifestyle [1]. The United 
Kingdom, Canada and United States of America have 
the highest incidence of breast cancer worldwide 
followed by the rest of North America, Australia and 
New Zealand [2]. In the current year, it is estimated that 
232,340 females and 2,240 males will be diagnosed 
with breast cancer in America. Of those diagnosed, 
39,620 females and 410 males will not survive [3]. 
There are several risk factors for developing breast 
cancer, including familial history, prolonged exposure 
to endogenous estrogens, alcohol use, obesity, and 
lack of physical activity. 
Currently, there are various strategies to treat 
breast cancer. When selecting the optimal treatment 
for a patient, physicians must take into account the 
stage of the cancer, sensitivity to certain hormones, 
and whether there is an increased expression of cer-
tain surface antigens on breast cancer cells [4]. The 
standard treatments for patients diagnosed with met-
astatic breast cancer include chemotherapy, radia-
tion, surgery, and targeted therapy using monoclonal 
antibodies [5-7]. Approximately 25% of breast cancer 
cells exhibit between two- and twenty-fold overex-
pression of HER2, a growth factor receptor whose ac-
tivation leads to downstream signaling regulating cel-
lular growth. Normal breast cells have approximately 
20,000 HER2 receptors, whereas breast cancer cells 
in aggressive tumors can have over 2 million. The in-
crease in the levels of HER2 receptors on cancer cells 
results in increased activation leading to excessive 
cellular division and tumor formation [8]. Common che-
motherapeutic drugs such as vinblastine, paclitaxel, 
anthracyclines, and doxorubicin are not always effec-
tive at treating metastatic breast cancer due to mul-
tidrug resistance [9,10]. Conventional treatments ad-
ministered to breast cancer patients have detrimental 
side-effects that occur due to poor target specificity [11]. 
One way to overcome this is by conjugating the drug 
to an antibody that is selective for a surface antigen 
that can differentiate cancer cells from normal healthy 
cells. These antibody-drug conjugates (ADCs) will un-
dergo a process of internalization (i.e. receptor-medi-
ated endocytosis) upon binding to the surface antigen 
(Figure 1a). A wide-range of anticancer compounds 
can be attached to the antibody of which natural prod-
ucts, metabolites derived from plants, fungi and mi-
crobes are among the most promising [12].
Natural products are routinely used in drug devel-
opment because they have highly potent bioactive 
properties as antibiotics (vancomycin), antifungals 
(cyclohexamide), and anticancer drugs (paclitaxel) [13]. 
For centuries, natural products have been used to treat 
ailments such as cancers and microbial infections [14]. 
In the last 50 years, 60% of cancer drugs have been 
derived from natural products or their analogues [15]. Il-
ludins are a relatively new class of sesquiterpenes – 
orange-yellow mushrooms found in the woodlands of 
North America [16]. Illudins possess the ability to inhibit 
the growth of various types of cancer cells at nanomo-
lar and even picomolar concentrations and are effec-
tive in treating multi-drug resistant tumours [17, 18, 19]. Il-
ludins primarily act as an alkylating agent; nucleophilic 
Illudins also inhibit the function of enzymes such as 
glutathione reductase (GR) and thioredoxin reductase 
(TrxR), which protect the cell against oxidative stress 
[21]. On their own, illudins lack specificity and do not
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Figure 1. Mechanisms of ADC targeting and cytotoxicity by Illudin S. (a) ADCs are selective towards cells 
that express the particular antigen that the monoclonal antibody has a strong affinity towards. Once the target-
specific antibody binds to the antigen, it undergoes a process of internalization. (b) Proposed mechanism of 
action of illudin S where there is first and enzymatic reduction by Nu1 (GR or NADPH) which subsequently 
reacts with Nu2 (H2O, DNA, protein). The highly unstable cyclopropyl ring increases the reactivity and cytotox-
icity of illudin S, making the unstable intermediate a potent alkylating agent.
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target cancer cells. However, when conjugated to a 
specific antibody, illudins may prove to be an excellent 
anticancer drug with the capability to target and elimi-
nate many types of cancers including breast cancer.
We propose to develop and test a modified illudin 
molecule through docking simulations and cytotoxicity 
assays. Subsequently, we can link this illudin analogue 
to a HER2 targeting monoclonal antibody (Trastuzumab) 
via a non-reducible thioether linker to produce SLAK-1, 
an antibody-drug conjugate that has the potential to se-
lectively target and eliminate breast cancer cells.
Main Proposal
R-group modification of illudin S (core) to produce 
illudin analogue
Illudin S, a natural illudin analogue that possess high 
cytotoxicity and low target specificity between malignant 
cells and normal cells, has a narrow therapeutic in-
dex (a ratio between the therapeutic effect of the drug 
versus the cytotoxicity of the drug itself) [22]. Acylful-
venes (AFs) and Hydroxymethylacylfulvene (HMAF), 
established derivatives of illudin, have improved ther-
apeutic indices. Both illudin S and AFs can react with 
and damage DNA, leading to cell death. AFs have the 
additional ability to inhibit GR, an enzyme that is up-
regulated in cancer cells to improve the regeneration 
of glutathione [22-23]. 
Using computer software, we modified side 
groups surrounding the core structure of illudin to de-
sign an analogue with increased affinity for GR and 
undiminished DNA cleavage activity. We added a 
COOCH2CH2SH group on carbon 7 (as labelled in fig-
ure 1b) of the main ring so that the maleimide group of 
SMCC, a crosslinking reagent, can be attached to the 
illudin via a sulfhydryl group. A strong nucleophilic side 
group of hydroxyurea acetate was added to carbon 6 
(as labelled in figure 1b) of the main ring to increase 
the toxicity of the molecule. Both of these modifica-
tions should increase binding affinity for glutathione 
reductase (GR). The hydroxyl group was replaced 
with methyl hydroxyl urea to offer more sites for nu-
cleophilic attack by thiol-containing proteins such as 
GR while preserving the pharmacophore of the illudin 
[24]. The mechanism of GR is shown in Figure 2. The 
addition of a methyl group was conducted to prevent 
any steric hindrance by the hydroxyurea. The linker 
region and the addition of an ethyl chain between 
the SH group and the ester group were designed
 a)
 b)
 Illudin S
         Nu1=GR or NADPH                           Nu2=H 2O, DNA, protein
 GR 
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to prevent steric hindrance  interfering with the mole-
cule’s pharmacophore, while adding an additional nu-
cleophilic attack site [25]. Additional ester groups were 
attached to increase the affinity of SLAK-1 for attack 
by the thiol group of GR to form a stable hydroxy-acyl 
group. To assess whether the modification increased 
binding affinity, we used in silico dockings to compare 
the affinities of our illudin analogue, illudin S, and irof-
ulven for GR. As expected, illudin S had the weakest 
binding affinity (highest ΔG), whereas our analogue 
had the strongest (lowest ΔG) (Figure 3). 
Conjugation of illudin analogue to trastuzumab 
to construct SLAK-1
To ensure that our illudin analogue selectively tar-
gets breast cancer cells, we propose its conjugation 
to trastuzumab to create an ADC named SLAK-1. 
Trastuzumab, also known as Herceptin, is a monoclo-
nal antibody that specifically binds to the HER2 recep-
tors embedded in the membranes of breast cancer 
cells [28]. The illudin should be attached to trastuzumab 
using a linker that cannot be cleaved until the ADC is 
fully internalized. We propose using the non-cleavable 
and membrane permeable crosslinker succinimidyl-
4-(N-maleimidomethyl) cyclohexane-1-carboxylate 
(SMCC). SMCC contains a reactive N-hydroxysuc-
cinimide (NHS ester) and a sulfhydryl-reactive ma-
leimide group. To link the antibody trastuzumab to our 
illudin analogue, SMCC should first be added to the 
antibody via the NHS ester group. Once the excess 
crosslinker reagent is removed, the illudin analogue 
should be added [29]. This two-step reaction will result 
in the formation of an ADC called SLAK-1 (Figure 4). 
Testing the cytotoxicity and specificity of SLAK-1
In order to test SLAK-1’s anti-cancer activity, we 
propose two assays: one for measuring the inhibition 
of GR, and the other for measuring DNA damage. 
GR is involved in the redox cycle that protects the 
cell against oxidative stress. The enzyme reduces 
glutathione disulfide (GSSG) to glutathione (GSH) 
by oxidizing NADPH to NADP+ (See reaction below).
GSSG + NADPH + H+                        2GSH + NADP+
We can indirectly measure GR inhibition by mea-
suring the rate of NADPH oxidation by a decrease in 
absorbance at 340 nm that corresponds to NADPH 
concentration [30]. Thus, one can measure the ability 
of SLAK-1 and other possible analogues to inhibit GR 
in vitro by measuring NADPH concentration in the
presence of various drug concentrations. The comet 
assay, also known as single cell gel electrophoresis, 
detects DNA damage in single cells [31]. We propose 
testing our SLAK-1 analogue against two breast can-
cer cell lines: KB and SK-Br-3 cells, which will subse-
quently be lysed and run on an electrophoresis gel. 
Once visualized, a smear mark resembling a comet 
will be reflective of DNA damage, when comparing 
the intensity ratios of the comet’s “head” to its “tail”.
If SLAK-1 inhibits the activity of GR and damages 
DNA in vitro, its efficacy should be tested against 
whole breast cancer cells in vitro. By comparing the 
growth inhibition of our breast cancer cell lines with 
that of normal fibroblast cells, we will assess the spec-
ificity of SLAK-1. We can also compare the analogue 
with and without the Trastuzumab antibody attached 
to the compound within a heterogeneous mixture of 
diseased and non-diseased cell types to test the ef-
ficacy of modified illudin analogue in vitro. Studying 
the effect of a human breast cancer xenograft in the 
murine (mouse) model can provide valuable insight 
into the growth and metastasis of the tumour in vivo. 
It can also identify host responses and potential side-
effects that may occur from the illudin analogue that 
can be administered as a Trastuzumab-attached 
compound. Severe combined immunodeficient (scid)
[32] mice would be injected with breast cancer cell 
lines (MCF7, ZR-75-1, and T47d). SLAK-1 can then 
be administered in a dose-dependent manner within 
the murine model via injection.
Conclusion
Given the proven clinical efficiency of ADCs 
against metastatic breast cancer in chemotherapy, 
the illudin-based drug proposed here might also have 
the desired effect against breast cancer tumours [33, 
34]. We have taken several important parameters into 
account in developing SLAK-1. First, to ensure po-
tent cytotoxicity against breast cancer cells, we have 
designed an illudin analogue that is able to efficiently 
inhibit GR and damage DNA. Assays for GR inhibi-
tion by illudin S and acylfulvene analogues have been 
published in the past [22]; however in silico modeling 
has not been published by any group. We used dock-
ing simulations to compare the binding affinities of 
several illudin analogues. As expected, illudin S and 
irofulven had weaker binding affinities (higher ΔG val-
ues) than our proposed illudin analogue. Altogether, 
this suggests that our drug will inhibit GR more ef-
ficiently and may prove to be more potent at inhibit-
ingthe growth of breast cancer cells once internalized. 
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Figure 2. Glutathione Reductase Inhibition by HMAF (modified acylfulvene derived from Illudin S). 
Above is the proposed mechanism by Liu and Sturla (2009) showing the inhibition of Glutathione Reductase 
by HMAF [22]. The sulfur from thiol containing proteins such as GR acts as a nucleophile and is added to the α,β 
unsaturated ketone; H2O is added to the cyclopropyl group thus inhibiting GR.
     GR docking simulation Compound Lowest estimated ΔG (kcal/mol)
           -7.103319
           -6.9755797
           -8.380411
Figure 3. In silico docking of Illudin S, Irofulven and SLAK-1 within GR. Docking simulations were carried 
out using SwissDock [26] to assess the ligand binding affinity of the various analogues to glutathione reductase 
(PDB: 3GRS). Hydrophobicity surfaces (Blue: hydrophilic, white: neutral, red: hydrophobic) were mapped ac-
cording to the Kyte-Doolittle scale in complex with their respective compounds using UCSF Chimera [27]. Three-
dimensional models were generated and respective affinities were estimated based on the lowest Gibbs Free 
Energy values within the corresponding binding pocket of GR.
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Figure 4. Construction of Antibody-Drug Conjugate SLAK-1 to target Her2 positive breast cancer. A 
SMCC non-cleavable linker is first added onto an antibody via NHS ester group. The excess SMCC reagent 
is then removed. The drug containing a sulfhydryl group is then added. This two-step reaction will result in the 
formation of an ADC called SLAK-1.
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Second, we have proposed the conjugation of our 
illudin analogue to the monoclonal antibody trastu-
zumab to ensure specificity towards breast cancer 
cells. Previous studies by Lewis Phillips et al. (2008) 
have validated the use of maytansenoid, a cytotoxic 
macrolide that inhibits the formation of microtubules, 
when conjugated to trastuzumab [35]. The specificity 
of this ADC for HER2-positive breast carcinomas in-
creases our confidence in the specificity of SLAK-1. 
If SLAK-1 is synthesized and successfully passes 
our proposed cytotoxicity and specificity tests, we will 
have overcome many difficulties associated with cur-
rent treatments for metastatic breast cancer. 
Keywords
Antibody-Drug Conjugate; Illudins; SLAK-1; Breast 
Cancer; HER 2 receptors; Trastuzumab; conjugué 
anticorps-médicament; illudines; cancer du sein; ré-
cepteurs HER-2.
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review of Characterizing RNF20 and RNF40 in the Class 
Switching of B Cells
This study describes a research plan to conjugate a synthetic proposed analog of the natural product illudin, 
called SLAK-1,  to the monoclonal antibody trastuzumab.  The proposal is based largely on the recent success 
of antibody-drug conjugates (ADCs) that have shown promising clinical results that have led to recent approv-
als by the FDA.  Because illudin functions as a cytotoxic agent through a unique mechanism of reduction by 
glutathione reductase, which is present in greater quantities in tumour cells versus normal cells, it is hoped that 
this approach would lead to a more selective ADC with a higher therapeutic index than those based on tubulin 
targeting agents such as Maytansine.
While there are several interesting concepts described, the manuscript appears to be more of a proposal 
than a report of actual results.  The basis of the actual work done only appears to be a simple molecular mod-
eling study with some proposed analogs showing how they dock into the binding site of glutathione reductase. 
In order to obtain impactful laboratory experimental results, a major effort would then be required to synthesize 
these analogs, test them and conjugate them.  
The author of this paper should be commended with proposing an extremely ambitious project and the ba-
sic idea behind the proposal has merit.  In addition, the background and nature of the project are actually quite 
interesting and could form the basis of a viable proposal.   However, some key flaws in the research plan itself 
make the research proposal, as it is layed out in this manuscript, unlikely to succeed.  There are many huge 
challenges that are glossed over in this proposal-the synthesis of the illudin analog, its characterization, and 
the challenges of conjugating it to trastuzumab that multiply the difficulty of succeeding in an actual research 
setting.  By removing as many variables as possible (for example sticking with a known drug to use in the con-
jugation) a complex research plan is more likely to succeed. 
The abstract for this paper is interesting and attracts the attention of the reader towards the proposed 
subject matter.  However, it is somewhat misleading in terms of what has been actually accomplished versus 
what is hypothetical.  In particular, by stating “a more potent analog of illudin” will be used as the conjugate it 
is implied that this analog has already been synthesized and characterized, when in fact it is only proposed 
based on crude modeling studies.  Not only is it not known that this is more potent, the proposed synthetic 
route to this analog is not disclosed.  What is known versus what is hypothetical should be more clearly stated. 
The introduction section is generally well written. A great deal of background information is provided to 
educate the reader about breast cancer, natural products and anti-body drug conjugates.  While each of these 
topics is enormous, the writers do a good job of providing an interesting and concise overview of each.  One 
deficiency of the introduction is an inadequate coverage of the recent advances that have been made in ADC 
development, both from the standpoint of comparative approaches in design, clinical results, and success in 
terms of FDA approvals.  Only a single reference from 2010 provided.  Suffice it to say, a huge number of ad-
vances have been made in the past two years that are not described here. 
Even if the  proposed analog SLAK-1 actually binds as well to GR as it is suggested in the main proposal, it 
is not clear what iterative process was used to derive this analog.  Rather than having just one analog to form 
the basis of the proposal (SLAK-1) would be of value to see how other designed analogs with various sub-
stituents compare so as to assess their potential.  In particular, while the rationale for the point of attachment 
of the thiol linker is good, the functionally dense nitrogen substituent appears to be unstable and synthetically 
challenging to install.  Moreover, the thought process for which this specific analog was designed is poorly 
conveyed.   Figure 3 is not clear in terms of the binding mode of the compounds and why SLAK-1 docks better 
than the other two compounds .  A clearer picture highlighting specific contacts or pockets would be helpful in 
interpreting the proposed advantages if SLAK-1.  
Aside from the above considerations, there are two key flaws to the proposed research.  The first is that 
SLAK-1 is likely to be an unstable, highly enolizable molecule with an acidic proton in the 5-membered ring 
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(position 8).  Because no specific synthetic plans are given for how this compound will be produced, these 
concerns become greater.  The second and perhaps more important issue is that there are no plans described 
for testing or evaluating this compound on its own, prior to conjugation, to evaluate its potential merits as a 
conjugation partner.  Instead, the proposal appears to entail making this compound (through undisclosed 
methods), conjugating it and then directly testing the ADC in vivo in tumour bearing mice.  This is a highly risky 
and extremely expensive approach.  Prior to carrying out any in vivo experiments, it is essential to evaluate 
the cytotoxity of the small molecule and compare it to a variety of other analogs to get a clearer understand-
ing of how SLAK-1 is likely to perform.  SLAK-1 should be tested preferably first in an in vitro setting such as 
in cytotoxity assays in tissue culture first, at a minimum.    In the section called “Validating the cytotoxicity and 
specificity of SLAK-1”, it is confusing if the authors are describing the SLAK-1 small molecule itself or the ADC 
in which it is incorporated.  If the latter, a new term such as SLAK-1 ADC should be used.
The most favourable part of the chemical aspects of the proposal is the actual plan for conjugating the natu-
ral product to trastuzumab.  A concise synthetic scheme is provided that appears reasonably viable.  However, 
the precedent for this scheme should be made more transparent in terms of what has been done with other 
ADCs.
In the conclusion section, some further aspects to ADC design are provided for consideration.  A good dis-
cussion of the rational for targeting HER-2 in breast cancer is given, and using trastuzumab as the antibody 
makes reasonable sense based on historical precedent.  An opportunity to clarify some key considerations 
should be taken here, however.  For example, it is stated that optimally 2-4 drug molecules /antibody should be 
used.  However, it isn’t clear how this will be achieved or if this number holds for all drug molecules.  Perhaps 
more important, criteria for how toxic the small molecule drug needs to be to merit consideration as a viable 
conjugation partner should be clarified.  Not having these criteria defined at the start of the research makes 
achieving a desired outcome much more difficult.
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